LUND, SWEDEN--(Marketwire - January 26, 2009) - The Election Committee has informed Active Biotech of its intention to submit the following proposals, among others, to the company’s Annual General Meeting to be held on May 7, 2009:
- The number of Board members shall be six and there shall be no Deputy Board members.
- Mats Arnhög, Klas Kärre, Magnhild Sandberg, Peter Sjöstrand and Peter Ström shall be re-elected.
- Tomas Nicolin shall be elected.
- Mats Arnhög shall be re-elected as Chairman of the Board.
- KPMG Bohlins AB shall be re-elected as Active Biotech’s audit firm.
External auditors are appointed by the Annual General Meeting for a period of four years. Election of auditors for the next four-year period will occur at the 2009 Annual General Meeting.
Tomas Nicolin, born in 1954, holds a degree in business administration from the Stockholm School of Economics and MIT Sloan School. Tomas Nicolin has many years of experience of executive positions in the financial sector, most recently as President of the retirement pension insurance company Alecta (2004-2008) and President of the Third AP Fund (1998-2004). Tomas Nicolin is a Board member of Nordstjernan AB, the Advisory Board of the Stockholm School of Economics, the Axel and Margaret Ax:son Johnson Foundation, the Research Institute of Industrial Economics, the Association for Generally Accepted Principles in the Securities Market and the Swedish Industry and Commerce Stock Exchange Committee.
The other proposals of the Election Committee concerning the election of the Chairman of the Annual General Meeting, Board fees and other areas will be presented in the invitation to the Annual General Meeting.
In addition to the Chairman of the Board, Mats Arnhög, the following individuals are members of the Election Committee: Johnny Sommarlund for MGA Holding, Tomas Billing for Nordstjernan and Ulf Strömsten for Catella Funds.
Lund, January 26, 2009
Active Biotech AB (publ)
Tomas Leanderson President and CEO For further information, please contact: Tomas Leanderson, President and CEO Tel: +46 46 19 20 95 tomas.leanderson@activebiotech.com Göran Forsberg, VP IR & Business Development Tel: +46 46 19 11 54 goran.forsberg@activebiotech.com
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on January 26, 2009, at 10:30 a.m.
Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00 www.activebiotech.com This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
